Guo-Qiang Zhou^*, Fu Han^*, Zhi-Liang Shi^*, Liang Yu^*, Xue-Feng Li^*, Cheng Yu^*, Cheng-Long Shen^*, Dai-Wei Wan^†, Xin-Guo Zhu^†, Rui Li^‡, Song-Bing He^†

Oncology Research, Vol.26, No.5, pp. 795-800, 2018, DOI:10.3727/096504017X15004613574679

Abstract Dysregulation of SUMO-specific protease 1 (SENP1) expression has been reported in several kinds of cancer, including human colorectal and prostate cancers, proposing SENP1 as an oncogene with a critical role in cancer progression. miR-133a-3p has been reported as a tumor suppressor in several malignant neoplasias. However, the precise molecular mechanisms underlying its role in colorectal cancer remain largely unknown. The aim of this work was to investigate the relationship between miR-133a-3p and SENP1 in colorectal cancer cells. We found that miR-133a-3p expression was downregulated in colorectal cancer tissues. In silico analyses indicated that SENP1 is More >

Enrico Mini^*, Ida Landini^*, Laura Lucarini^†, Andrea Lapucci^*, Cristina Napoli^‡, Gabriele Perrone^*, Renato Tassi^*, Emanuela Masini^†, Flavio Moroni^†, Stefania Nobili^‡

Oncology Research, Vol.26, No.2, pp. 333-334, 2018, DOI:10.3727/096504018X15187172557369

Abstract The poly(ADP-ribose) polymerase (PARP) enzymes play a key role in the regulation of cellular processes (e.g., DNA damage repair, genomic stability). It has been shown that PARP inhibitors (PARPIs) are selectively cytotoxic against cells having dysfunctions in genes involved in DNA repair mechanisms (synthetic lethality). Drug-induced PARP inhibition potentiates the activity of anticancer drugs such as 5-fluorouracil in enhancing DNA damage, whose repair involves PARP-1 activity. The aim of this study was to evaluate the inhibitory effects of a novel PARPI, HYDAMTIQ, on growth in human tumor cell lines characterized by different features with regard… More >

Doris P. Yimgang¹, John D. Sorkin², Charles F. Evans³, Danielle S. Abraham¹, Geoffrey L. Rosenthal^1,4

Congenital Heart Disease, Vol.13, No.4, pp. 533-540, 2018, DOI:10.1111/chd.12622

Abstract Introduction: Angiotensin converting enzyme inhibitors are commonly prescribed medications after the Norwood procedure. There are little data that can be used to determine if angiotensin converting enzyme inhibitors improve interstage outcomes in children with single ventricle defects. The objective of this study was to investigate the relationship between angiotensin converting enzyme inhibitors and interstage failure among infants born with hypoplastic left heart syndrome.
Methods: We conducted a retrospective cohort study using data from the National Pediatric Cardiology Quality Improvement Collaborative database (collected between 2008 and 2015). We used logistic regression models to assess the exposure-outcome associations and… More >

Enrico Mini^*, Ida Landini^*, Laura Lucarini^†, Andrea Lapucci^*, Cristina Napoli^‡, Gabriele Perrone^*, Renato Tassi^*, Emanuela Masini^†, Flavio Moroni^†, Stefania Nobili^‡

Oncology Research, Vol.25, No.9, pp. 1441-1451, 2017, DOI:10.3727/096504017X14926854178616

Abstract The poly(ADP-ribose) polymerase (PARP) enzymes play a key role in the regulation of cellular processes (e.g., DNA damage repair, genomic stability). It has been shown that PARP inhibitors (PARPIs) are selectively cytotoxic against cells having dysfunctions in genes involved in DNA repair mechanisms (synthetic lethality). Drug-induced PARP inhibition potentiates the activity of anticancer drugs such as 5-fluorouracil in enhancing DNA damage, whose repair involves PARP-1 activity. The aim of this study was to evaluate the inhibitory effects of a novel PARPI, HYDAMTIQ, on growth in human tumor cell lines characterized by different features with regard… More >

Maitham A. Khajah, Princy M. Mathew, Yunus A. Luqmani

Oncology Research, Vol.25, No.8, pp. 1283-1295, 2017, DOI:10.3727/096504017X14883245308282

Abstract Current mainstream pharmacological options for the treatment of endocrine-resistant breast cancer have limitations in terms of their side effect profile and lack of discrimination between normal and cancer cells. In the current study, we assessed the responses of normal breast epithelial cells MCF10A, estrogen receptorpositive (ER+ ) MCF-7, and ER-silenced pII breast cancer cells to inhibitors (either individually or in combination) of downstream signaling molecules. The expression/activity of ERK1/2, p38 MAPK, and Akt was determined by Western blotting. Cell proliferation, motility, and invasion were determined using MTT, wound healing, and Matrigel assays, respectively. Morphological changes… More >

Susanna Cattarino¹, Thomas Seisen^1,2, Sarah J. Drouin¹, Raphaële Renard-Penna¹, Priscilla Leon^1,2, Eva Comperat³, Pierre Mozer¹, Olivier Cussenot^1,2, Morgan Rouprêt^1,2

Canadian Journal of Urology, Vol.22, No.2, pp. 7703-7708, 2015

Abstract Introduction: To assess the impact of statin use on biochemical recurrence (BCR) of prostate cancer after radical prostatectomy (RP).
Materials and methods: Data from all men treated with robot-assisted laparoscopic RP (RALRP) for localized prostate cancer between 2009 and 2014 at our institution were prospectively collected: age, body mass index (BMI), statin-use status, preoperative prostate-specific antigen (PSA) level, clinical T stage, biopsy Gleason score (bGS), D'Amico risk group, pathological T stage, specimen Gleason score (sGS), multifocality, perineural invasion, positive surgical margins and time to BCR. Univariate and multivariate analysis were performed to test associations between statin… More >

Hong Truong^1,*, Jennifer Logan^1,*, Baris Turkbey², M. Minhaj Siddiqui¹, Soroush Rais-Bahrami¹, Anthony N. Hoang¹, Chad Pusateri¹, Brian Shuch¹, Annerleim Walton-Diaz¹, Srinivas Vourganti¹, Jeffrey Nix¹, Lambros Stamatakis¹, Colette Harris¹, Celene Chua¹, Peter L. Choyke², Bradford J. Wood³, Peter A. Pinto^1,3

Canadian Journal of Urology, Vol.20, No.6, pp. 7002-7007, 2013

Abstract Introduction: Prior studies of volumetric effects of 5α-reductase inhibitors (5ARIs) on the prostate have used transrectal ultrasound which provides poor differentiation of prostatic zones. We utilized high-resolution prostate MRI to evaluate the true dynamic effects of 5ARI in men who underwent multiple MRIs.
Materials and methods: A retrospective study of patients who underwent serial 3.0 Tesla prostate MRI from 2007 to 2012 and were treated with 5ARI were studied. Nineteen patients who had a baseline MRI prior to 5ARI initiation and subsequent MRI follow up were selected. A randomly selected group of 40 patients who had not… More >

Stephen Faddegon, Sara L. Best, Ephrem O. Olweny, Yung K. Tan, Samuel K. Park, Saad A. Mir, Jeffrey A. Cadeddu

Canadian Journal of Urology, Vol.19, No.3, pp. 6274-6279, 2012

Abstract Introduction: Growing evidence suggests that phosphodiesterase-5 inhibitors may mitigate ischemia-related renal damage through multiple mechanisms. We evaluated the role of tadalafil in renal function preservation during experimentally induced ischemia/reperfusion injury (IRI) in a solitary kidney porcine model.
Materials and methods: Ten adult female pigs underwent left laparoscopic nephrectomy followed by a 1 week recovery period. They were then randomized to tadalafil versus no treatment prior to cross-clamping the contralateral renal hilum for 90 minutes. The experimental group received 40 mg tadalafil in two equally divided doses, 12 hours before and just prior to surgery. Serum creatinine for… More >

Nathalie Cathala¹, Annick Mombet¹, Rafael Sanchez-Salas¹, Francois Rozet¹, Eric Barret¹, Francois Giuliano², Marc Galiano¹, Dominique Prapotnich¹, Amir Kazzazi³, Bob Djavan³, Jamison Jaffe¹, Xavier Cathelineau¹, Guy Vallancien¹

Canadian Journal of Urology, Vol.19, No.4, pp. 6328-6335, 2012

Abstract Introduction: To evaluate erectile function among men who had undergone laparoscopic radical prostatectomy and received postoperative medical therapy for erectile dysfunction.
Materials and methods: We performed a prospective study in men who underwent laparoscopic radical prostatectomy between September 2003 and November 2005 at our center and who received penile rehabilitation after surgery. All patients had antegrade interfascial dissection. They received 10 mg tadalafil on the fifth postoperative day and continued to receive it every other day, regardless of erectile function. Intracavernous injection of alprostadil was initiated at 3 or 6 months depending on response to treatment with… More >

Daniel Canter, Alexander Kutikov, Konstantin Golovine, Petr Makhov, Jay Simhan, Robert G. Uzzo, Vladimir M. Kolenko

Canadian Journal of Urology, Vol.18, No.4, pp. 5819-5825, 2011

Abstract Objectives: We examined the in vitro cellular effects of the multi-targeted receptor tyrosine kinase inhibitors (TKIs) sunitinib and pazopanib on a series of human renal cell carcinoma (RCC) cell lines.
Methods: The human RCC cell lines 769-P, 786-O, HRC-24, HRC-31, HRC-45, HRC-78, SK-26B, and SK-45 were treated with varying concentrations of sunitinib and pazopanib. Cellular proliferation and cell death were assessed using the CellTiter-Blue Cell Viability Assay and the TUNEL assay, respectively. Effective doses (ED) for inhibition of cellular proliferation or induction of apoptosis were calculated for both sunitinib and pazopanib in each RCC cell line.
Results: Both… More >